Gülden Özek
Gülden Özek has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Asuman Doğan Bayrak1 shared publication
- Bedirhan Albayrak
Department of Orthopaedics and Traumatology, Samsun Training and Research Hospital, Samsun, Turkey
1 shared publication - Dorukhan Demir1 shared publication
- Ebru Erdemoğlu
Department of Obstetrics and Gynaecology, Faculty of Medicine, Suleyman Demirel University, 32260 Isparta, Turkiye
1 shared publication - Elif Kandemir Ekinci1 shared publication
- Gülal Karsenas1 shared publication
Latest Publications
- Open Access
- 20 August 2026
- Published by Balikesir Medical Journal in Balıkesir Medical Journal
- Vol. 10 (2) , 59-66
The Complementary Role of Diffusion-Weighted MRI in the Evaluation of Renal Lesions: A Retrospective Study
Objective: The aim of this study was to evaluate the diffusion-weighted magnetic resonance imaging (DWI) findings of renal masses and to assess the complementary role and limitations of apparent diffusion coefficient (ADC) measurements in routine clinical practice. Materials and Methods: This retrospective, single-center study included 50 renal lesions detected on abdominal magnetic resonance imaging examinations performed between 2009 and 2011. Lesions were classified as benign or malignant based on histopathological confirmation or characteristic imaging findings with clinical follow-up. Diffusion-weighted imaging was performed using b-values of 0 and 1000 s/mm², and ADC measurements were obtained by placing regions of interest within the lesions while avoiding necrotic or hemorrhagic areas. ADC values of renal lesions and adjacent normal renal parenchyma were recorded and compared. Interobserver agreement between two radiologists was assessed using the intraclass correlation coefficient (ICC). Results: Of the 50 renal lesions, 25 were benign and 25 were malignant. Malignant lesions demonstrated significantly lower mean ADC values (1.43 ± 0.73 ×10⁻³ mm²/s) compared with benign lesions (2.76 ± 0.98 ×10⁻³ mm²/s) (p < 0.001). Inflammatory lesions exhibited intermediate ADC values, showing partial overlap between benign and malignant groups. Interobserver agreement for ADC measurements was high. Conclusion: Diffusion-weighted MRI provides complementary information in the evaluation of renal masses by reflecting tissue diffusion characteristics. However, due to overlapping ADC values among different lesion types, its diagnostic value is limited when used in isolation. ADC measurements should be interpreted together with conventional MRI findings and clinical information in routine practice.
- 20 August 2026
- Published by Balikesir Medical Journal in Balıkesir Medical Journal
- Vol. 10 (2) , 59-66
Open AccessThe Complementary Role of Diffusion-Weighted MRI in the Evaluation of Renal Lesions: A Retrospective Study
Objective: The aim of this study was to evaluate the diffusion-weighted magnetic resonance imaging (DWI) findings of renal masses and to assess the complementary role and limitations of apparent diffusion coefficient (ADC) measurements in routine clinical practice. Materials and Methods: This retrospective, single-center study included 50 renal lesions detected on abdominal magnetic resonance imaging examinations performed between 2009 and 2011. Lesions were classified as benign or malignant based on histopathological confirmation or characteristic imaging findings with clinical follow-up. Diffusion-weighted imaging was performed using b-values of 0 and 1000 s/mm², and ADC measurements were obtained by placing regions of interest within the lesions while avoiding necrotic or hemorrhagic areas. ADC values of renal lesions and adjacent normal renal parenchyma were recorded and compared. Interobserver agreement between two radiologists was assessed using the intraclass correlation coefficient (ICC). Results: Of the 50 renal lesions, 25 were benign and 25 were malignant. Malignant lesions demonstrated significantly lower mean ADC values (1.43 ± 0.73 ×10⁻³ mm²/s) compared with benign lesions (2.76 ± 0.98 ×10⁻³ mm²/s) (p < 0.001). Inflammatory lesions exhibited intermediate ADC values, showing partial overlap between benign and malignant groups. Interobserver agreement for ADC measurements was high. Conclusion: Diffusion-weighted MRI provides complementary information in the evaluation of renal masses by reflecting tissue diffusion characteristics. However, due to overlapping ADC values among different lesion types, its diagnostic value is limited when used in isolation. ADC measurements should be interpreted together with conventional MRI findings and clinical information in routine practice.
- Open Access
- 20 January 2026
- Published by Academician Publishing
Multidisciplinary Approaches In Gynecological Oncology
- 20 January 2026
- Published by Academician Publishing
Open AccessMultidisciplinary Approaches In Gynecological Oncology
- 20 January 2026
- Published by Academician Publishing
- p. 47-70
Imaging in Gynecological Cancers
Gynecological cancers of the cervix, endometrium, ovary, vulva, and vagina remain a major global health burden, with rising incidence and mortality underscoring the need for accurate diagnosis, staging, and treatment planning. Imaging is central to every step of the patient pathway. Ultrasound, particularly transvaginal ultrasound, is the first-line modality for evaluating uterine and adnexal pathology, enabling early detection, assessment of tumor extent, and guidance of biopsy, with risk stratification enhanced by standardized systems such as O-RADS and structured reporting. Computed tomography (CT) provides rapid whole-abdomen and thoracic assessment for nodal and distant metastases, while magnetic resonance imaging (MRI) offers superior soft-tissue contrast and functional techniques such as diffusion-weighted and dynamic contrast-enhanced imaging, which are now embedded in modern FIGO staging of cervical and endometrial cancers. For ovarian and adnexal masses, MRI and O-RADS MRI refine characterization of indeterminate lesions and optimize surgical planning. Molecular imaging, particularly 18F-FDG PET-CT, contributes to accurate staging, detection of recurrence, assessment of treatment response, and radiotherapy planning, with emerging roles for PET-MRI and novel tracers, including hypoxia- and receptor-targeted agents. Hybrid PET-MRI integrates high-resolution anatomic, functional, and metabolic data with reduced radiation dose, showing promise in complex pelvic disease and recurrent malignancy. Increasingly, artificial intelligence, deep learning, radiomics, and radiogenomics enable extraction of quantitative imaging biomarkers that capture tumor heterogeneity, support prognostication, and may predict treatment response. The integration of multiparametric imaging with AI-driven analysis is poised to advance precision, standardization, and personalization in the management of gynecological cancers.
- 20 January 2026
- Published by Academician Publishing
- p. 47-70
Imaging in Gynecological Cancers
Gynecological cancers of the cervix, endometrium, ovary, vulva, and vagina remain a major global health burden, with rising incidence and mortality underscoring the need for accurate diagnosis, staging, and treatment planning. Imaging is central to every step of the patient pathway. Ultrasound, particularly transvaginal ultrasound, is the first-line modality for evaluating uterine and adnexal pathology, enabling early detection, assessment of tumor extent, and guidance of biopsy, with risk stratification enhanced by standardized systems such as O-RADS and structured reporting. Computed tomography (CT) provides rapid whole-abdomen and thoracic assessment for nodal and distant metastases, while magnetic resonance imaging (MRI) offers superior soft-tissue contrast and functional techniques such as diffusion-weighted and dynamic contrast-enhanced imaging, which are now embedded in modern FIGO staging of cervical and endometrial cancers. For ovarian and adnexal masses, MRI and O-RADS MRI refine characterization of indeterminate lesions and optimize surgical planning. Molecular imaging, particularly 18F-FDG PET-CT, contributes to accurate staging, detection of recurrence, assessment of treatment response, and radiotherapy planning, with emerging roles for PET-MRI and novel tracers, including hypoxia- and receptor-targeted agents. Hybrid PET-MRI integrates high-resolution anatomic, functional, and metabolic data with reduced radiation dose, showing promise in complex pelvic disease and recurrent malignancy. Increasingly, artificial intelligence, deep learning, radiomics, and radiogenomics enable extraction of quantitative imaging biomarkers that capture tumor heterogeneity, support prognostication, and may predict treatment response. The integration of multiparametric imaging with AI-driven analysis is poised to advance precision, standardization, and personalization in the management of gynecological cancers.